文献速递肝病

肝病与2019冠状病毒病:从发病机制到临床诊疗

Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
PubMed 文献 · Hepatology · 2021-06-18

本文综述SARS-CoV-2与肝脏的相互作用及肝病对COVID-19临床结局的影响。COVID-19中肝脏受累常见,表现从无症状肝酶升高到肝失代偿;肝酶异常与更严重的COVID-19表现和总体死亡率相关。肝硬化患者感染COVID-19与肝失代偿和肝相关死亡相关,医疗资源压力亦影响慢性肝病患者的诊疗。

要点

  • COVID-19患者肝脏受累常见,可从无症状肝酶升高至肝失代偿。
  • 肝酶异常与COVID-19更严重表现及总体死亡率相关。
  • 肝硬化患者感染COVID-19与肝失代偿和肝相关死亡相关。

核心结论

  • COVID-19中肝脏受累常见,肝酶异常与更严重疾病表现和总体死亡率相关。
  • 肝硬化患者感染COVID-19与肝失代偿和肝相关死亡相关。
  • SARS-CoV-2是否在肝细胞内有效感染复制并直接致病尚不明确。

研究设计与样本

  • 本文为综述,总结SARS-CoV-2与肝脏的病毒-宿主相互作用及肝病在COVID-19中的临床影响。

主要发现

  • COVID-19肝脏受累表现从无症状肝酶升高到肝失代偿不等。
  • 肝酶异常与COVID-19更严重表现和总体死亡率相关。
  • 已在COVID-19患者肝脏中检测到SARS-CoV-2 RNA,但是否有效感染复制并直接致病尚不明确。
  • COVID-19肝损伤原因涉及病毒诱导的系统性炎症、缺氧、肝淤血和药物性肝病等多因素。
  • 肝硬化患者感染COVID-19与肝失代偿和肝相关死亡相关,医疗资源影响可不利影响慢性肝病诊疗。

临床怎么用

  • 应认识COVID-19患者肝脏受累的多种表现并监测肝功能。
  • 对肝硬化等晚期肝病患者应关注COVID-19相关肝失代偿和肝相关死亡风险。
  • 管理COVID-19肝损伤需考虑系统性炎症、缺氧、肝淤血和药物性肝病等多因素。

局限性

  • SARS-CoV-2是否在肝细胞内有效感染复制并直接致病尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that emerged in late 2019, is posing an unprecedented challenge to global health. Coronavirus disease 2019 (COVID-19), the clinical disease caused by SARS-CoV-2, has a variable presentation ranging from asymptomatic infection to life-threatening acute respiratory distress syndrome and multiorgan failure. Liver involvement is common during COVID-19 and exhibits a spectrum of clinical manifestations from asymptomatic elevations of liver function tests to hepatic decompensation. The presence of abnormal liver tests has been associated with a more severe presentation of COVID-19 disease and overall mortality. Although SARS-CoV-2 RNA has been detected in the liver of patients with COVID-19, it remains unclear whether SARS-CoV-2 productively infects and replicates in liver cells and has a direct liver-pathogenic effect. The cause of liver injury in COVID-19 can be attributed to multiple factors, including virus-induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. Among patients with cirrhosis, COVID-19 has been associated with hepatic decompensation and liver-related mortality. Additionally, COVID-19's impact on health care resources can adversely affect delivery of care and outcomes of patients with chronic liver disease. Understanding the underlying mechanisms of liver injury during COVID-19 will be important in the management of patients with COVID-19, especially those with advanced liver disease. This review summarizes our current knowledge of SARS-CoV-2 virus-host interactions in the liver as well the clinical impact of liver disease in COVID-19.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Saviano A, Wrensch F, Ghany MG, et al. Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. Hepatology. 2021. PMID: 33332624. doi:10.1002/hep.31684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。